Comparison · NCT01790659-sae
WR 279,396 vs Paromomycin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. WR 279,396 vs Paromomycin: serious adverse events. Trial comparisons, record NCT01790659-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01790659-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00995 | 0.00273 | 0.0355 | wilson | |
| Risk in group 2 | 0.00505 | 0.000892 | 0.028 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0049 | -0.0192 | 0.0308 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.97 | 0.18 | 21.6 | log | |
| Odds ratio, group 1 over group 2 | 1.98 | 0.178 | 22 | log | |
| Number needed to harm, for one more participant with a serious adverse event on WR 279,396 than on Paromomycin | 204 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | WR 279,396 | (Paromomycin and Gentamicin Topical Cream)~WR 279,396: WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5% | 2 | 201 | EG000 |
| Group 2 | Paromomycin | Paromomycin alone~Paromomycin: Paromomycin alone | 1 | 198 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- AE's were assessed at baseline, days 2-9 daily, day 20, 35, 49, 63, 100, and 168 (applicable)
Source ClinicalTrials.gov
Trial
- Title
- Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
- NCT number
- NCT01790659
- Phases
- PHASE3
- Conditions
- Cutaneous Leishmaniasis
- Interventions
- WR 279,396, Paromomycin
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Results first posted
- 2017-08-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01790659?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01790659-sae